ADAURA: exploratory eight-year overall survival update for adjuvant osimertinib in resected EGFR-mutated stage IB to IIIA lung cancer
Eight years after surgery, about three in four patients who took osimertinib for three years were still alive, compared with under six in ten on placebo: the longest survival follow-up from any global adjuvant trial in EGFR-mutated lung cancer.
Overview
Post hoc exploratory analysis of long-term overall survival in ADAURA, the phase 3 trial that randomised 682 patients with resected EGFR-mutated stage IB to IIIA non-small-cell lung cancer to three years of adjuvant osimertinib or placebo. Survival data were collected from 431 of the 558 patients alive at the planned final overall survival analysis (data cut-off 27 January 2023) through yearly follow-up to a new cut-off of 4 May 2026; the 127 patients without further follow-up stayed censored at the earlier cut-off.
In the stage II to IIIA population the overall survival hazard ratio was 0.53 (95 percent CI 0.38 to 0.75) and eight-year survival was 74 percent with osimertinib against 58 percent with placebo. In the stage IB to IIIA population the hazard ratio was 0.52 (95 percent CI 0.39 to 0.71) with eight-year survival of 79 percent against 64 percent. Hazard ratios by mutation were 0.45 for exon 19 deletions and 0.72 (95 percent CI 0.46 to 1.11) for L858R, and the benefit was seen across subgroups.
- Stage II to IIIA: eight-year overall survival 74 percent with osimertinib vs 58 percent with placebo; hazard ratio 0.53 (95 percent CI 0.38 to 0.75); median follow-up 92.0 vs 68.5 months.
- Stage IB to IIIA: eight-year overall survival 79 percent vs 64 percent; hazard ratio 0.52 (95 percent CI 0.39 to 0.71); median follow-up 93.3 vs 79.6 months.
- Overall survival hazard ratio 0.45 (95 percent CI 0.29 to 0.68) for exon 19 deletion and 0.72 (95 percent CI 0.46 to 1.11) for L858R.
The survival benefit first reported in 2023 has held five years after the last dose of adjuvant osimertinib, which answers the worry that a three-year course only delays relapse. Patients with an exon 19 deletion gained most; the L858R estimate crosses one and is less certain. Nothing here changes the recommendation, which already rests on the 2023 analysis, but it tightens the case for testing every resected non-squamous tumour for EGFR mutations.
- Post hoc exploratory analysis, not a prespecified endpoint, with unequal follow-up between arms.
- Follow-up was obtained for 431 of 558 patients alive at the 2023 cut-off; the remaining 127 were censored at the earlier date, so the eight-year estimates rest on partial ascertainment.
- The L858R hazard ratio (0.72, 95 percent CI 0.46 to 1.11) is not statistically significant on its own.
Similar pages
not linked directly; found by shared links- Key paperADAURA: three years of osimertinib after surgery for EGFR-mutated lung cancer
Shares Shun Lu, Yi-Long Wu, Roy S. Herbst, ADAURA.
- InstitutionChinese Thoracic Oncology Group
Shares Shun Lu, Yi-Long Wu, ADAURA, Non-small-cell lung cancer.
- TrialDurvalumab With Stereotactic Body Radiation Therapy (SBRT) vs Placebo With SBRT in Early Stage Unresected Non-small Cell Lung Cancer (NSCLC) Patients/ Osimertinib Following SBRT in Patients With Early Stage Unresected NSCLC Harboring an EGFR Mutation
Shares Resectable stage I to III non-small-cell lung cancer, Osimertinib, EGFR-mutated non-small-cell lung cancer, AstraZeneca.
- TrialA Study of 5 Years of Adjuvant Osimertinib in Completely Resected Epidermal Growth Factor Receptor Mutation (EGFRm) Non-small Cell Lung Carcinoma (NSCLC)
Shares Resectable stage I to III non-small-cell lung cancer, Osimertinib, AstraZeneca, Non-small-cell lung cancer.
- TrialSH-1028 Tablets Versus Placebo as Adjuvant Therapy in Resected Stage II-IIIB NSCLC With Sensitizing EGFR Mutations
Shares Resectable stage I to III non-small-cell lung cancer, EGFR-mutated non-small-cell lung cancer, EGFR, Non-small-cell lung cancer.
- TrialStudy to Assess the Efficacy and Safety of Adjuvant Osimertinib in NSCLC With Uncommon EGFRm
Shares Resectable stage I to III non-small-cell lung cancer, Osimertinib, AstraZeneca, Non-small-cell lung cancer.
- TrialA Global Study to Assess the Effects of Osimertinib in Participants With EGFRm Stage IA2-IA3 NSCLC Following Complete Tumour Resection
Shares Osimertinib, EGFR-mutated non-small-cell lung cancer, AstraZeneca, Non-small-cell lung cancer.
- TrialPhase II Study of Sacituzumab Tirumotecan in Combination With Osimertinib for Neoadjuvant Treatment in Patients With Resectable Epidermal Growth Facto
Shares Resectable stage I to III non-small-cell lung cancer, Osimertinib, EGFR-mutated non-small-cell lung cancer, Non-small-cell lung cancer.